Identification of a novel pro-apopotic function of NF-κB in the DNA damage response

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 10, 2009, Pages 4239-4256

  Karl, Sabine ^a   Pritschow, Yvonne ^a   Volcic, Meta ^b   Häcker, Sabine ^a   Baumann, Bernd ^b   Wiesmüller, Lisa ^b   Debatin, Klaus Michael ^a   Fulda, Simone ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Apoptosis; DNA damage; Glioblastoma; NF B

Indexed keywords

DNA; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCALATING AGENT; PROTEIN P53; PROTEIN BINDING;

APOPTOSIS; ARTICLE; CELL CYCLE; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; PROTEIN BINDING; TRANSCRIPTION INITIATION; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; DNA, NEOPLASM; DOXORUBICIN; GLIOBLASTOMA; HUMANS; INTERCALATING AGENTS; NF-KAPPA B; PROTEIN BINDING; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77449136821     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00888.x     Document Type: Article

References (50)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001, 344:114-23.
2. Furnari FB, Fenton T, Bachoo RM. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-710.
3. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006, 12:440-50.
4. Christmann M, Tomicic MT, Roos WP. Mechanisms of human DNA repair: an update. Toxicology. 2003, 193:3-34.
5. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007, 28:739-45.
6. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006, 13:759-72.
7. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 2007, 19:142-9.
8. Karin M, Cao Y, Greten FR. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-10.
9. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-224.
10. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008, 132:344-62.
11. Janssens S, Tinel A, Lippens S. PIDD mediates NF-kappaB activation in response to DNA damage. Cell. 2005, 123:1079-92.
12. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ 2006, 13:773-84.
13. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996, 274:784-7.
14. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell. 2004, 13:853-65.
15. Campbell KJ, O'Shea JM, Perkins ND. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer. 2006, 6:101.
16. Ho WC, Dickson KM, Barker PA. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res. 2005, 65:4273-81.
17. La Ferla-Bruhl K, Westhoff MA, Karl S. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene. 2007, 26:571-82.
18. Trauzold A, Wermann H, Arlt A. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene. 2001, 20:4258-69.
19. Brendler-Schwaab S, Hartmann A, Pfuhler S. The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis. 2005, 20:245-54.
20. Beneke S, Diefenbach J, Burkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer. 2004, 111:813-8.
21. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3:17-26.
22. Weaver KD, Yeyeodu S, Cusack JC. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol. 2003, 61:187-96.
23. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res. 1996, 24:4242-8.
24. Ammann JU, Haag C, Kasperczyk H. Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. Int J Cancer. 2009, 124:1301-11.
25. Mattson MP. NF-kappaB in the survival and plasticity of neurons. Neurochem Res. 2005, 30:883-93.
26. Herrmann O, Baumann B, de Lorenzi R. IKK mediates ischemia-induced neuronal death. Nat Med. 2005, 11:1322-9.
27. Pizzi M, Goffi F, Boroni F. Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1beta. J Biol Chem. 2002, 277:20717-23.
28. Qin ZH, Chen RW, Wang Y. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci. 1999, 19:4023-33.
29. Panet H, Barzilai A, Daily D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem. 2001, 77:391-8.
30. Bian X, McAllister-Lucas LM, Shao F. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem. 2001, 276:48921-9.
31. Bhoopathi P, Chetty C, Kunigal S. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem. 2008, 283:1545-52.
32. Hewson QD, Lovat PE, Corazzari M. The NF-kappaB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells. Apoptosis. 2005, 10:493-8.
33. Kasperczyk H, La Ferla-Bruhl K, Westhoff MA. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene. 2005, 24:6945-56.
34. Grilli M, Pizzi M, Memo M. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996, 274:1383-5.
35. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-8.
36. Roos WP, Batista LF, Naumann SC. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007, 26:186-97.
37. Batista LF, Roos WP, Christmann M. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res. 2007, 67:11886-95.
38. Perkins ND. NF-kappaB: tumor promoter or suppressor. Trends Cell Biol. 2004, 14:64-9.
39. Hayashi S, Yamamoto M, Ueno Y. Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurol Med Chir. 2001, 41:187-95.
40. Yamamoto M, Fukushima T, Hayashi S. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res. 2000, 20:611-8.
41. Nagai S, Washiyama K, Kurimoto M. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg. 2002, 96:909-17.
42. Angileri FF, Aguennouz M, Conti A. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer. 2008, 112:2258-66.
43. Wang H, Zhang W, Huang HJ. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest. 2004, 84:941-51.
44. Korkolopoulou P, Levidou G, Saetta AA. Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol. 2008, 39:1143-52.
45. Baumann B, Bohnenstengel F, Siegmund D. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem. 2002, 277:44791-800.
46. Denk A, Goebeler M, Schmid S. Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem. 2001, 276:28451-8.
47. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296:550-3.
48. Vogler M, Durr K, Jovanovic M. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene. 2007, 26:248-57.
49. Opel D, Westhoff MA, Bender A. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res. 2008, 68:6271-80.
50. Fulda S, Friesen C, Los M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997, 57:4956-64.